Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer adjuvant therapy.

Leora Horn1, Alan Sandler

  • 1Department of Medicine, University of Toronto, Toronto, ON, Canada.

Cancer Journal (Sudbury, Mass.)
|July 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Nature medicine·2025
Same author

Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC.

Clinical lung cancer·2025
Same author

Afatinib and Necitumumab in <i>EGFR</i>-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.

JTO clinical and research reports·2025
Same author

Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2024

Neoadjuvant and adjuvant therapies improve outcomes for non-small cell lung cancer (NSCLC) patients after surgery. This review examines evidence for chemotherapy, radiation, and combined treatments to reduce NSCLC recurrence.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Oncology

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in North America.
  • Despite surgical advances, NSCLC recurrence rates after resection can reach 50%.

Purpose of the Study:

  • To review the rationale and evidence for neoadjuvant and adjuvant therapies in resected NSCLC.
  • To evaluate the role of chemotherapy, radiation therapy, and combined modality treatments.

Main Methods:

  • Literature review of studies on neoadjuvant and adjuvant therapies for NSCLC.
  • Analysis of evidence supporting various treatment modalities.

Main Results:

  • Neoadjuvant and adjuvant therapies are crucial for improving outcomes in resected NSCLC.

Related Experiment Videos

  • Evidence supports the use of chemotherapy, radiation, and combined approaches.

    • Conclusions:

    • Adjuvant and neoadjuvant treatments offer significant benefits for patients with resected NSCLC.
    • Multimodal therapy is essential for improving survival and reducing recurrence in NSCLC.